Local management of metastatic breast cancer will improve the overall survival: a systematic review and meta-analysis study

Abstract

Author(s): Mahfuz Ghaderi, Mohammad Esmaiel Akbari, Atieh Akbari, Haniyeh Bahsizadeh Fakhar, Sadegh Khoddam, Bashirjamail Wa-hidi

Background: In women, Breast Cancer (BC) is the most common cancer as well as second cause of death due to cancer. Metastatic Breast Cancer (BC) occurs at diagnosis in about 6% of BC patients and develops in 20%– 50% of patients during their lifetimes.

Method: We performed a systematic review of empirical quantitative studies using the PRISMA statement, the Cochrane guidelines, and instructions for synthesis without meta-analysis in systematic reviews. We performed a systematic review of empirical quantitative studies using the PRISMA statement, the Cochrane guidelines, and instructions for synthesis without meta-analysis in systematic reviews. The analyses were performed using stata software, version 17.

Results: The primary interventions used in the studies were Radiotherapy (RT), Stereotactic Body Radiotherapy (SBRT), Stereotactic Ablative Body Radiotherapy (SABR), and surgery. The duration of OS in studies ranged from 2 years to 5 years. The Overall Survival (OS) rates varied widely, from 45% to 95%, with the highest survival rates observed in studies that utilized SBRT or a combination of SBRT and Intensity-Modulated Radiotherapy (IMRT). The overall pooled effect size OS across all studies was 67.43% (95% CI: 57.68- 77.17).

Conclusion: These findings advocate for the integration of surgical approaches in the treatment regimen for breast cancer, suggesting that loco regional therapy may offer substantial survival advantages, while also highlighting the need for careful consideration of the timing and context of such interventions.

Share this article